News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
559,154 Results
Type
Article (41815)
Company Profile (100)
Press Release (517239)
Section
Business (158371)
Career Advice (2459)
Deals (28697)
Drug Delivery (92)
Drug Development (75977)
Employer Resources (142)
FDA (14059)
Job Trends (12604)
News (282375)
Policy (27871)
Tag
Academia (2627)
Alliances (40082)
Alzheimer's disease (1293)
Approvals (13996)
Artificial intelligence (137)
Bankruptcy (307)
Best Places to Work (10230)
Breast cancer (178)
Cancer (1312)
Cardiovascular disease (116)
Career advice (2067)
CAR-T (94)
Cell therapy (272)
Clinical research (60883)
Collaboration (424)
Compensation (153)
COVID-19 (2508)
C-suite (117)
Data (1348)
Diabetes (162)
Diagnostics (5659)
Earnings (56290)
Employer resources (130)
Events (76731)
Executive appointments (374)
FDA (14675)
Funding (387)
Gene therapy (197)
GLP-1 (606)
Government (4197)
Healthcare (16580)
Infectious disease (2604)
Inflammatory bowel disease (109)
Interviews (523)
IPO (12839)
Job creations (2740)
Job search strategy (1701)
Layoffs (400)
Legal (5871)
Lung cancer (202)
Manufacturing (177)
Medical device (10937)
Medtech (10941)
Mergers & acquisitions (15986)
Metabolic disorders (437)
Neuroscience (1627)
NextGen Class of 2024 (5774)
Non-profit (4151)
Northern California (1450)
Obesity (244)
Opinion (193)
Parkinson's disease (92)
Patents (112)
People (51198)
Phase I (18494)
Phase II (26803)
Phase III (20640)
Pipeline (501)
Postmarket research (2386)
Preclinical (7597)
Radiopharmaceuticals (210)
Rare diseases (258)
Real estate (4414)
Regulatory (19202)
Research institute (2244)
Resumes & cover letters (363)
Southern California (1260)
Startups (2913)
United States (12735)
Vaccines (557)
Weight loss (185)
Date
Today (109)
Last 7 days (499)
Last 30 days (2238)
Last 365 days (31526)
2024 (31105)
2023 (35244)
2022 (45853)
2021 (49268)
2020 (47880)
2019 (41228)
2018 (31425)
2017 (28294)
2016 (26998)
2015 (31536)
2014 (23727)
2013 (19385)
2012 (20621)
2011 (21641)
2010 (19219)
Location
Africa (745)
Arizona (116)
Asia (34781)
Australia (7030)
California (3198)
Canada (1290)
China (275)
Colorado (145)
Connecticut (139)
Europe (77155)
Florida (475)
Georgia (115)
Illinois (327)
Indiana (200)
Maryland (567)
Massachusetts (2366)
Michigan (156)
Minnesota (226)
New Jersey (974)
New York (936)
North Carolina (616)
Northern California (1450)
Ohio (127)
Pennsylvania (756)
South America (1026)
Southern California (1260)
Texas (470)
Utah (101)
Washington State (348)
559,154 Results for "immutep formerly known as prima biomed".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Immutep Quarterly Activities Report Q3 FY24
Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, provides an update on the ongoing development of its product candidates, eftilagimod alpha (efti) and IMP761 for the quarter ended 31 March 2024 (Q3 FY24).
April 29, 2024
·
7 min read
Press Releases
Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
November 15, 2024
·
5 min read
Press Releases
Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II
December 16, 2024
·
4 min read
Drug Development
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024
Immutep Limited today announces encouraging efficacy, safety, and pharmacodynamic data from the safety lead-in of the AIPAC-003 Phase II/III trial presented at the European Society for Medical Oncology (ESMO) Breast Cancer 2024 Congress.
May 15, 2024
·
5 min read
Immutep successfully completes institutional placement and institutional component of entitlement offer
Immutep Limited ACN 009 237 889 is pleased to announce the successful completion of its institutional placement and the institutional component of its 1 for 16 pro rata accelerated non-renounceable entitlement offer of new fully paid ordinary shares in Immutep.
June 5, 2024
·
7 min read
Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer
Immutep Limited announces a License Agreement with Cardiff University granting the Company exclusive rights to develop and commercialise anti-LAG-3 small molecules.
June 25, 2024
·
4 min read
Press Releases
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761
December 17, 2024
·
4 min read
Press Releases
Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024
December 12, 2024
·
4 min read
Press Releases
Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
December 11, 2024
·
2 min read
Biotech Bay
Science Corporation Acquires Pixium’s PRIMA Retinal Implant, Extending and Diversifying Its Commitment to Vision Restoration Through Brain-Computer Interface Technology
Science Corporation has acquired the IP and related assets for the PRIMA retinal implant.
April 25, 2024
·
3 min read
1 of 55,916
Next
